Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

81. Randomised controlled trial: The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs

Randomised controlled trial: The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you (...) are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional

Evidence-Based Medicine (Requires free registration)2014

82. Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomized controlled trial

Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomized controlled trial Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomized controlled trial Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): a randomized controlled trial Pitkala KH, Poysti MM, Laakkonen ML, Tilvis RS, Savikko N, Kautiainen H, Strandberg TE Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the impact of exercise on health and social service costs and physical functioning, for patients with Alzheimer's disease. The authors concluded that exercise administered in the patient's home could slow the decline in physical functioning, without increasing costs. The study

NHS Economic Evaluation Database.2013

83. Leuco-methylthioninium for alzheimer's disease

Leuco-methylthioninium for alzheimer's disease Leuco-methylthioninium for alzheimer's disease Leuco-methylthioninium for alzheimer's disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Leuco-methylthioninium for alzheimer's disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 (...) Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alzheimer Disease; Humans; Methylene Blue Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414

Health Technology Assessment (HTA) Database.2013

84. NeuroAD? for mild and moderate Alzheimer's Disease

NeuroAD? for mild and moderate Alzheimer's Disease NeuroAD™ for mild and moderate Alzheimer's Disease NeuroAD™ for mild and moderate Alzheimer's Disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. NeuroAD™ for mild and moderate Alzheimer's Disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon (...) Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alzheimer Disease /therapys Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44

Health Technology Assessment (HTA) Database.2013

85. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease. BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients (...) with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living

NEJM2013

86. Screening for predementia Alzheimer's disease: time-dependent operating characteristics of episodic memory tests

Screening for predementia Alzheimer's disease: time-dependent operating characteristics of episodic memory tests 23468542 2013 04 02 2013 05 23 2016 10 19 1526-632X 80 14 2013 Apr 02 Neurology Neurology Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. 1307-14 10.1212/WNL.0b013e31828ab2c9 Data from the Einstein Aging Study (EAS) were used to prospectively evaluate the free recall score from the free and cued selective reminding test (FCSRT-FR (...) ) and logical memory I immediate recall (LM-IR) subtest of the Wechsler memory scale-revised for prediction of incident Alzheimer disease (AD) dementia among individuals from a community-based cohort with memory complaints. Analyses included 854 participants, age ≥70 years, who initially had no dementia, and had memory complaints. Clinic evaluations were completed annually and AD dementia was diagnosed using standard criteria (n = 86 cases; average follow-up 4.1 years). Time-dependent

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

87. Alzheimer disease and risk of stroke: a population-based cohort study

Alzheimer disease and risk of stroke: a population-based cohort study 23303851 2013 02 19 2013 05 16 2013 02 19 1526-632X 80 8 2013 Feb 19 Neurology Neurology Alzheimer disease and risk of stroke: a population-based cohort study. 705-11 10.1212/WNL.0b013e31828250af To investigate the risk of stroke in patients clinically diagnosed with Alzheimer disease (AD) compared with non-AD patients with similar vascular risk factors. Using data obtained from Taiwan's National Health Insurance Research (...) , with an adjusted hazard ratio of 1.70 (95% confidence interval, 1.03-2.79, p = 0.037). Clinical diagnosis of AD is associated with considerably increased risk of stroke development. Chi Nai-Fang NF Department of Neurology, Shuang Ho Hospital, Taipei Medical University, Taiwan. Chien Li-Nien LN Ku Hsiao-Lun HL Hu Chaur-Jong CJ Chiou Hung-Yi HY eng Journal Article 2013 01 09 United States Neurology 0401060 0028-3878 AIM IM Adult Aged Aged, 80 and over Alzheimer Disease complications epidemiology Case-Control

EvidenceUpdates2013

88. Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies.

Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies. This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the cross-sectional diagnostic accuracy of [index test] at various thresholds for ADD and other dementias [target condition] in [target population].ORTo determine the accuracy of [index test] at various thresholds

Cochrane2013

89. Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease.

Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease. Regulatory innovation and drug development for early-stage Alzheimer's disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item (...) : 23484795 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2013 Mar 28;368(13):1169-71. doi: 10.1056/NEJMp1302513. Epub 2013 Mar 13. Regulatory innovation and drug development for early-stage Alzheimer's disease. 1 , . 1 Division of Neurology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring

NEJM2013

90. Ginkgo biloba extract did not reduce risk for Alzheimer disease in elderly patients with memory complaints.

Ginkgo biloba extract did not reduce risk for Alzheimer disease in elderly patients with memory complaints. ACP Journal Club. Ginkgo biloba extract did not reduce risk for Alzheimer disease in elderly patients with memory complaints. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail (...) Order My Bibliography Citation manager Format Create File 1 selected item: 23318341 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2013 Jan 15;158(2):JC7. doi: 10.7326/0003-4819-158-2-201301150-02007. ACP Journal Club. Ginkgo biloba extract did not reduce risk for Alzheimer disease in elderly patients with memory complaints. 1 . 1

Annals of Internal Medicine2013

91. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease ? a simulation study

Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease ? a simulation study Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease – a simulation study Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease – a simulation study Skoldunger A, Johnell K, Winblad B, Wimo (...) A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of a hypothetical disease-modifying treatment for Alzheimer's disease. The authors concluded that it was reasonable to think that the treatment

NHS Economic Evaluation Database.2013

92. Cohort study: Use of psychotropic medication in Alzheimer's disease is associated with more rapid cognitive and functional decline

Cohort study: Use of psychotropic medication in Alzheimer's disease is associated with more rapid cognitive and functional decline Use of psychotropic medication in Alzheimer's disease is associated with more rapid cognitive and functional decline | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of psychotropic medication in Alzheimer's disease is associated with more rapid cognitive and functional decline Article Text Harm Cohort study Use of psychotropic medication in Alzheimer's disease is associated with more rapid cognitive and functional

Evidence-Based Medicine (Requires free registration)2013

93. Alzheimer's disease is associated with increased risk of haemorrhagic stroke

Alzheimer's disease is associated with increased risk of haemorrhagic stroke Alzheimer's disease is associated with increased risk of haemorrhagic stroke | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Alzheimer's disease is associated with increased risk of haemorrhagic stroke Article Text Aetiology Alzheimer's disease is associated with increased risk of haemorrhagic stroke Statistics from Altmetric.com No Altmetric data available for this article. Question Question: Are community-dwelling people with Alzheimer's disease at increased risk

Evidence-Based Mental Health2013

94. Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine

Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine | Evidence-Based Medicine This site uses cookies. By continuing to browse the site (...) -to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Article Text Therapeutics Randomised controlled trial Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Pierre N Tariot Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Howard R , McShane R , Lindesay J , et al

Evidence-Based Medicine (Requires free registration)2013

95. The DAISY psychosocial intervention does not improve outcomes in patients with mild Alzheimer's disease or their carers

The DAISY psychosocial intervention does not improve outcomes in patients with mild Alzheimer's disease or their carers The DAISY psychosocial intervention does not improve outcomes in patients with mild Alzheimer's disease or their carers | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The DAISY psychosocial intervention does not improve outcomes in patients with mild Alzheimer's disease or their carers Article Text Therapeutics The DAISY psychosocial intervention does not improve outcomes in patients with mild Alzheimer's disease

Evidence-Based Mental Health2013

96. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Hartz S, Getsios D, Tao S, Blume S, Maclaine G Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of donepezil, for the treatment of Alzheimer’s disease, versus memantine or no treatment, in Germany. The authors concluded that donepezil was highly cost-effective. The methods were appropriate

NHS Economic Evaluation Database.2013

97. Intravenous Immunoglobulin Therapy for the Treatment of Alzheimer?s Disease

Intravenous Immunoglobulin Therapy for the Treatment of Alzheimer?s Disease "Intravenous Immunoglobulin Therapy for the Treatment of Alzheimer’s Di" by Kathryn L. Williams < > > > > > Title Author Date of Award Summer 8-8-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Alzheimer’s disease (AD) is the 6th leading cause of death and affects 5.4 million Americans. It is thought to be caused, in part, by the deposition (...) of β-amyloid plaques in the brain. Intravenous immunoglobulin (IVIg) is a medication with a reputable safety record that contains natural anti-β-amyloid (Aβ) antibodies. Decades of research have led to the proposal of IVIg for the treatment of AD. Method: An exhaustive search of medical literature was conducted. Key words searched included: intravenous immunoglobulin, Alzheimer’s disease, immunotherapy, and Aβ. Articles were screened to fit criteria and assessed using the GRADE method. Results

Pacific University EBM Capstone Project2013

98. Vizamyl (flutemetamol F 18 injection) - A radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia

Vizamyl (flutemetamol F 18 injection) - A radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia Drug Approval Package: Vizamyl NDA #203137 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Vizamyl (Flutemetamol F 18) Company: GE Healthcare, Inc. Application No.: 203137 Approval Date: 10/25/2013 Persons with disabilities having problems

FDA - Drug Approval Package2013

99. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease. 23883379 2013 07 25 2013 08 02 2016 10 25 1533-4406 369 4 2013 Jul 25 The New England journal of medicine N. Engl. J. Med. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. 341-50 10.1056/NEJMoa1210951 Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein (...) . Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog

NEJM2013